Hypertension + CKD medication decisions

Structured approach to blood pressure control with renal-risk guardrails and follow-up checkpoints.

High-risk workflowLast reviewed September 4, 2026

AI-assisted evidence review. Clinical-owner sign-off is not recorded for this update.

Scope

Use for

Adult outpatient hypertension management with CKD medication safety checks.

Not for

Children, pregnancy, and preconception hypertension need separate guidance.
Hypertensive emergency or unstable acute presentation.
Advanced CKD scenarios requiring specialist-led medication strategy.

Immediate actions

Confirm BP with standardized technique and a validated device; use home or ambulatory readings to confirm the diagnosis.
Check creatinine/eGFR, potassium, urine ACR, current drugs, adherence, and volume status before medication changes.
Review NSAIDs, OTC products, orthostatic symptoms, and pregnancy potential.

Red flags: escalate now

If any of these are present, stop routine steps and follow the urgency stated. Activate emergency care for instability or findings that need immediate transfer.

New neurologic deficit, chest pain, pulmonary edema, or other suspected acute target-organ injury: arrange emergency assessment.
Rapid renal deterioration, symptomatic hypotension, or severe hyperkalemia needs urgent assessment according to severity.

First-line plan

The 2025 Canadian primary-care guideline defines hypertension as BP at least 130/80 mmHg under standardized conditions; treatment initiation is a separate decision.
Start pharmacotherapy at BP at least 140/90, or systolic 130-139 with high cardiovascular risk. Aim for systolic below 130 if tolerated; individualize for frailty, falls, and postural symptoms.
When drugs are indicated, initial low-dose combination therapy is recommended, ideally in one pill: choose two of ACEi/ARB, thiazide or thiazide-like diuretic, and long-acting dihydropyridine CCB.
In albuminuric CKD, use an ACEi or ARB when indicated and tolerated; never combine ACEi and ARB. Pair treatment with lifestyle and adherence support.

Follow-up and monitoring

Check BP, creatinine, and potassium within 2-4 weeks after ACEi/ARB initiation or titration; arrange earlier testing when renal or potassium risk warrants it.
A creatinine rise over 30% within four weeks requires evaluation for reversible causes and treatment reassessment. Do not stop a tolerated ACEi/ARB solely because eGFR falls below 30.
Persistent hypertension despite three appropriate drugs including a diuretic warrants adherence/secondary-cause review and specialist input; without acute organ injury this is not itself a hypertensive emergency.

Linked resources

Tools and calculators

eGFR (CKD-EPI) calculator

Prescribing aids

Before the patient leaves

Return precautions you can say as written:

“If symptoms get worse, new warning signs appear, or you cannot follow the plan from this visit, seek urgent care now.”

Point to the red flags above that apply to this patient.
Confirm follow-up timing and where to go after hours.
Attach a relevant handout to reinforce the plan.
Document disposition, rationale, unresolved uncertainty, and that precautions were understood.

About this workflow

Clinical owner: Family Medicine Editorial Team
Risk tier: High
Review cadence: Every 6 months
Last reviewed: September 4, 2026AI-assisted evidence review. Clinical-owner sign-off is not recorded for this update.
Review status: Evidence current. Next review due March 4, 2027.